Treatment of Pulmonary Neuroendocrine Tumor in Atypical Lung Carcinoid with N2 Lymph Node Metastases

Atypical lung carcinoid (AC) with N2 lymph node metastases carries a particularly high risk of relapse. In this select subgroup, adjuvant strategies beyond surgery require careful multidisciplinary evaluation.

Clinical scenario: Atypical lung carcinoid with N2 lymph node metastases in fit patients with a particularly high risk of relapse, considered after multidisciplinary discussion.

Treatment Approach

Adjuvant cytotoxic chemotherapy — or radiotherapy — may be considered in this high-risk setting. The chemotherapy component involves specific cytotoxic classes; radiotherapy may be used in combination or as a standalone alternative.

Full regimen detail, sequencing, and drug-class specifics are in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2021.01.003

However, it may be considered in selected fit patients with particularly high risk of relapse (i.e. AC N2) after multidisciplinary discussion [IV, C].
However, cytotoxic ChT (dacarbazine/temozolomide- or oxaliplatin-based ChT) ± RT may be considered in selected fit patients with a particularly high risk of relapse (i.e. AC N2) after multidisciplinary discussion [IV, C].

View source ↗